Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective

被引：2

作者：

Xu, Xu Steven ^{[1
]}

Yan, Xiaoyu ^{[1
]}

Puchalski, Thomas ^{[2
]}

Lonial, Sagar ^{[3
]}

Lokhorst, Henk M. ^{[4
]}

Voorhees, Peter M. ^{[5
]}

Liu, Kevin ^{[1
]}

Khan, Imran ^{[1
]}

Jansson, Richard ^{[2
]}

Ahmadi, Tahamtan ^{[2
]}

Ruixo, Juan Jose Perez ^{[6
]}

Zhou, Honghui ^{[2
]}

Clemens, Pamela L. ^{[2
]}

机构：

[1] Janssen Res & Dev LLC, Raritan, NJ USA

[2] Janssen Res & Dev LLC, Spring House, PA USA

[3] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA

[4] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[5] Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Hematol Oncol, Chapel Hill, NC 27599 USA

[6] Janssen Res & Dev, Beerse, Belgium

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

10.1182/blood.V126.23.4254.4254

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 41 条

[21] Low Dose Daily Corticosteroid Tapering Regimen Allows Highly Effective and Practical Desensitization for Multiple Myeloma Patients with Skin Rash after Immunomodulatory Drugs
Firoozmand, Amin
Ali, Naveed
Ahmed, Nausheen
Fu, Pingfu
Cao, Shufen
Brown, George
Schmikla, Hannah
Driscoll, James J.
O'Brien, Timothy
Caimi, Paolo
de Lima, Marcos
Malek, Ehsan
BLOOD, 2020, 136
[22] Pomalidomide, daratumumab, and dexamethasone after lenalidomide treatment in patients with relapsed or refractory multiple myeloma (RRMM): final overall survival analysis of the phase 2 MM-014 study
Bahlis, Nizar
Samaras, Christy
Reece, Donna
Sebag, Michael
Matous, Jeffrey
Berdeja, Jesus
Shustik, Jesse
Schiller, Gary
Ganguly, Siddhartha
Song, Kevin
Seet, Christopher
Acosta-Rivera, Mirelis
Quick, Donald
Anz, Bertrand
Fonseca, Gustavo
Liu, Hongjuan
Gentili, Christian
Siegel, David
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S162 - S162
[23] Pomalidomide, Daratumumab, and Dexamethasone After Lenalidomide Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): Final Overall Survival (OS) Analysis of the Phase II MM-014 Study
Bahlis, Nizar J.
Samaras, Christy
Reece, Donna
Sebag, Michael
Matous, Jeffrey
Berdeja, Jesus G.
Shustik, Jesse
Schiller, Gary J.
Ganguly, Siddhartha
Song, Kevin
Seet, Christopher S.
Acosta-Rivera, Mirelis
Quick, Donald
Anz, Bertrand
Fonseca, Gustavo
Liu, Hongjuan
Gentili, Christian
Siegel, David S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S494 - S495
[24] Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone
Morgan, Gareth
Palumbo, Antonio
Dhanasiri, Sujith
Lee, Dawn
Weisel, Katja
Facon, Thierry
Delforge, Michel
Oriol, Albert
Zaki, Mohamed
Yu, Xin
Sternas, Lars
Jacques, Christian
Akehurst, Ron
Offner, Fritz
Dimopoulos, Meletios A.
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (06) : 820 - 823
[25] Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
Lugui Qiu
Zhongjun Xia
Chengcheng Fu
Wenming Chen
Chunkang Chang
Baijun Fang
Gang An
Yongqiang Wei
Zhen Cai
Sujun Gao
Jianyu Weng
Lijuan Chen
Hongmei Jing
Fei Li
Zhuogang Liu
Xiequn Chen
Jing Liu
Aihua Wang
Yang Yu
Wenxi Xiang
Kevin Lynch
Zhinuan Yu
Weijun Fu
BMC Medicine, 20
[26] Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
Qiu, Lugui
Xia, Zhongjun
Fu, Chengcheng
Chen, Wenming
Chang, Chunkang
Fang, Baijun
An, Gang
Wei, Yongqiang
Cai, Zhen
Gao, Sujun
Weng, Jianyu
Chen, Lijuan
Jing, Hongmei
Li, Fei
Liu, Zhuogang
Chen, Xiequn
Liu, Jing
Wang, Aihua
Yu, Yang
Xiang, Wenxi
Lynch, Kevin
Yu, Zhinuan
Fu, Weijun
BMC MEDICINE, 2022, 20 (01)
[27] Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study
Terpos, Evangelos
Kastritis, Efstathios
Hatjiharissi, Evdoxia
Katodritou, Eirini
Papaiakovou, Evangelos Eleutherakis
Verrou, Evgenia
Gavriatopoulou, Maria
Leonidakis, Alexandros
Ntanasis-Stathopoulos, Ioannis
Delimpasi, Sosana
Kyrtsonis, Marie-Christine
Papaioannou, Maria
Symeonidis, Argiris
Dimopoulos, Meletios A.
BLOOD, 2021, 138
[28] Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study
Richardson, Paul G.
Baz, Rachid
Wang, Luhua
Jakubowiak, Andrzej J.
Berg, Deborah
Liu, Guohui
Gupta, Neeraj
Di Bacco, Alessandri
Hui, Ai-Min
Lonial, Sagar
BLOOD, 2011, 118 (21) : 140 - 140
[29] Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)
Qiu, Lugui
Fu, Weijun
Xia, Zhongjun
Fu, Zhengzheng
Chen, Wenming
Chang, Chunkang
Fang, Baijun
An, Gang
Wei, Yongqiang
Cai, Zhen
Gao, Sujun
Weng, Jianyu
Chen, Lijuan
Jing, Hongmei
Fei, Li
Liu, Zhuogang
Chen, Xiequn
Liu, Jing
Yu, Yang
Wang, Aihua
Yang, Yijun
Yu, Zhinuan
Lynch, Kevin
BLOOD, 2021, 138
[30] A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug ( IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naive to Daratumumab (dara)
Kumar, Shaji K.
Cornell, Robert F.
Landgren, Ola
Ailawadhi, Sikander
Higgins, Jack P.
Willert, Erin K.
Waltzman, Roger
Lin, Jianchang
Zhang, Yuhong
Lublinsky, Anya R.
Dash, Ajeeta B.
Hanley, Michael
Manoharan, Divya
Leichter, Morgan
Ottinger, Sean
Labotka, Richard J.
Newcomb, John
Vorog, Alexander
BLOOD, 2019, 134

← 1 2 3 4 5 →